Schedule a Meeting
Download Brochure
Table of Content
April 2025
The global cell line development market size is calculated at US$ 5.86 in 2024, grew to US$ 6.44 billion in 2025, and is projected to reach around US$ 14.92 billion by 2034. The market is expanding at a CAGR of 9.85% between 2025 and 2034. New paths have been opened for cell line development (CLD) due to the increased availability of transcriptomic and genomic resources, which help to develop cell lines, coupled with advances in genome editing technology. This newly developed cell line helps in the manufacturing of biosimilars.
Unlock Infinite Advantages: Subscribe to Annual Membership
The expiration of biologics has increased the demand for biosimilars. Thus, this increased the production of cell lines for the development of new biologics, biosimilars, and protein therapeutics. Currently, most biopharmaceutical companies are using the glutamine synthetase (GS) system or methotrexate (MTX) amplification technology for the development of mammalian cell lines. Highly heterogeneous cell clones are obtained by these methods due to random genome integration with the gene of interest and the gene amplification process. Furthermore, these cell clones are screened to identify the stable high-producer cell clones. Moreover, there is an increasing demand for new technologies as these technologies can't be used for large-scale production.
The AI models can be used for the prediction of protein structure in structural biology, computational biology, and computer science. This was made possible by using the data of the Protein Data Bank (PDB), which consists of protein structural information from diverse species over 50 years. Other than structure prediction, these AI models are being used to design new proteins with specific functions, which can be used in developing new therapeutics, biomaterials with unique properties as well and enzymes for industrial applications. Furthermore, the molecular interactions between proteins are also being identified by these models. Thus, as these AI tools are guiding experimental design and hypothesis generation, the research in cell biology is being enhanced.
Increasing Demand for Biologics
Biologics show effectiveness in treating various diseases like cancer or autoimmune disorders. The increasing number of diseases is increasing their demand. The personalized medications depending on the disease and patient profile are also increasing the biologics demand. They are also being used in healthcare systems as they are cost-effective. Due to these reasons, the research and development sectors are focusing on the development of new advances in biologics. Thus, to enhance the development as per the rising needs, the government, as well as the regulatory agencies, is supporting the research and development sectors, which in turn increase the cell line development market.
The graph represents the total number of approved and in-development cell line therapies. It shows that the gene therapies in development are maximum, which will in turn enhance market growth, providing an increased number of treatment options for the diseases.
Contamination Risk
In the cell line development, there is a risk of contamination of the cell line. This could be due to various reasons, such as microbial contamination, cross-contamination, improper sterilization, manual errors, etc. Because of this, the quality of the product is hampered as well, and it may become unsafe to use. Hence, it is essential to prevent contamination. Thus, it becomes important that the cell line should be maintained properly in a suitable environment to avoid contamination.
Gene Editing
By using gene-editing technology, various modifications can be made in cell lines, which can be further used for developing customized cell lines or personalized medications. The researchers are using this technology as it can be used for the optimization of protein expression and increasing the yield. Due to this, the production of biologics such as monoclonal antibodies and vaccines becomes easier. Furthermore, different cell-based and gene therapies can also be developed efficiently. Thus, all these factors, along with the regulatory support, are increasing the demand for gene editing.
For instance,
By product & service type, the reagents and media segment dominated the market in 2024. Reagents and media provide nutrients that are utilized for cell line development. It provided control and consistency in the cell line development during large-scale production. It was also used in vaccine development and toxicological studies. This contributed to the cell line development market growth.
By product & service type, the services segment is estimated to be the fastest-growing at a notable CAGR during the forecast period. Due to the increasing demand for advanced therapies like cell therapies and gene therapies for different diseases, the CLD services have increased. At the same time, services providing technological advancements are increasing outsourcing by reducing the cost and time required in production.
By source type, the mammalian cell line segment dominated the market in 2024 and is predicted to be the fastest-growing during the forecast period. Mammalian cell lines helped in the production of biologics such as therapeutic proteins, monoclonal antibodies, and vaccines. It developed high-quality biologics with essential modifications. It also produced and optimized the genetic modifications. All these factors resulted in market growth.
By type of cell lines, the recombinant cell lines segment dominated the global cell line development market in 2024. It was used in the production of proteins such as therapeutic proteins and monoclonal antibodies. It provided consistency in the production as well as was available at affordable prices. It is also used in different vaccines and medications for a variety of diseases. This enhanced the market growth.
By type of cell lines, the hybridomas segment is expected to be the fastest-growing during the forecast period. Hybridomas are mostly used in cancer treatment for the production of various therapeutics. They are also used in the development of targeted therapies as well as biosimilars and biologics. Thus, due to these factors, it is promoting market growth.
By application type, the bioproduction segment dominated the global market in 2024. Bioproduction helped in the development of various biologics. It offered large-scale manufacturing with an affordable production process. It also helped in the development of personalized medications. This contributed to the cell line development market growth.
By application type, the tissue engineering segment is anticipated to be the fastest-growing during the forecast period. Tissue engineering is being used for the development of artificial tissues and organs for transplantations. Regenerative and personalized medicines are also produced by this technique. Furthermore, it is showing advancements in drug testing, cosmetic research, and stem cell research. Thus, due to all these factors, the market is rising.
North America dominated the cell line development market share by 40% in 2024. North America consisted of advanced healthcare facilities that were adopting cell culture techniques. At the same time, the research and development sector also focused on developing new cell lines with government support. This contributed to the market growth.
A large number of biotechnological and pharmaceutical industries in the U.S. are contributing to the development of cell lines. This production is carried out on a large scale for formulating new biologics or biosimilars. Moreover, to support them, the government is providing investments and funding, which further drive the market.
Various healthcare systems are shifting towards the use of cell lines for treatment options. The use of cell lines or protein therapeutics is as per the guidelines of regulatory bodies, which attracts the patients. At the same time, collaborations of companies for cell line development are also enhancing market growth.
Asia Pacific is estimated to host the fastest-growing cell line development market during the forecast period. The demand for biopharmaceuticals is rising in the Asia Pacific. At the same time, biotechnology and pharmaceutical industries are evolving, which results in increased research and development of new cell lines or biopharmaceuticals. These factors together are responsible for the rise in market growth.
Different industries in China are focusing on the development of new biopharmaceuticals, which is supported by government initiatives. This helps in rapid manufacturing on a large scale, which in turn makes the biopharmaceutical available to the healthcare systems. Similarly, research institutes are also contributing to the development of new biopharmaceuticals. Thus, this results in market growth.
There is a rise in the demand for vaccines and biosimilars, which causes increased demand for the production of cell lines. The industries in India are advancing, which in turn is increasing the production and optimization of these cell lines. Furthermore, due to affordable prices, the patients, as well as the export demand, have increased. All these factors contribute to market growth.
Europe is expected to be significantly growing in the cell line development market during the forecast period. Various industries in Europe are adapting to technological advancements, which helps in the increased production of cell lines. Furthermore, these cell lines are being used in personalized medications or targeted therapy, which is increasing public demand and, thus, enhancing market growth.
The manufacturing rates in Germany are increasing due to technological advancements. At the same time, research and development sectors are focusing on the development of new biotechnological innovations. Moreover, the demand for personalized medications has increased the use of cell lines, contributing to the market growth.
The UK is facing an increasing demand for gene and cell therapies. This, in turn, has increased the production and innovation in cell lines. Thus, the government and private sectors are continuously investing in the development process. At the same time, new collaborations between the companies are being formed for the development of targeted and personalized medications. All these factors are resulting in the growth of the market.
In April 2025, Dr. Conklin said that gene-editing technologies like CRISPR/Cas9 could be used in treating Charcot-Marie-Tooth disease (CMT). He further stated that the project they are working on can provide blueprints for the therapeutic editing of the dominant forms of CMT. They aim to overcome critical technical barriers, such as screening the number of CRISPR designs as well as validating its efficiency in human neurons.
In March 2025, a new Glyoxalase Domain-containing Protein 4 (GLOD4) was identified by Nitrase Therapeutics, which can generate Nitrated Alpha-synuclein, a hallmark of Parkinson's Disease (PD). While introducing it, the chief executive officer of Nitrase Therapeutics, Irene Griswold-Prenner, Ph.D. stated, stated that it is a significant achievement to discover a protein with a completely new type of enzymatic activity, and it is a therapeutic target for Parkinson's disease, which is an exciting prospect for a difficult-to-treat disease.
By Product & Service
By Source
By Type of Cell Lines
By Application
By Region
April 2025
March 2025
March 2025
March 2025